| Oct 9 |
Longboard Pharmaceuticals Inc (LBPH) Q2 2024 Earnings Call Highlights: Promising Clinical ...
|
| Oct 1 |
Longboard Pharmaceuticals gains amid takeover speculation
|
| Sep 27 |
Longboard Pharmaceuticals begins Phase III Dravet syndrome trial
|
| Sep 26 |
Longboard Pharmaceuticals Initiates Phase 3 DEEp SEA Study Evaluating Bexicaserin in Dravet Syndrome
|
| Sep 20 |
Longboard Stock Soars on FDA Designations for Epilepsy Drug
|
| Sep 19 |
Longboard Pharma gains on FDA designations for lead asset
|
| Sep 19 |
Longboard Pharmaceuticals Receives Rare Pediatric Disease Designation and Orphan Drug Designation for Bexicaserin (LP352) in Dravet Syndrome
|
| Sep 9 |
Longboard reports interim data from Phase II extension trial of DEEs treatment
|
| Sep 8 |
Longboard Pharmaceuticals Announces Positive Interim Analysis Results from the Open-Label Extension (OLE) of the Phase 1b/2a PACIFIC Study Evaluating Bexicaserin in Participants with Developmental and Epileptic Encephalopathies (DEEs)
|
| Aug 28 |
Longboard Pharmaceuticals to Participate in Four Upcoming Investor Conferences in September
|
